Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer

We aimed to determine the prevalence of HPV-16/18 antibodies in Korean women with high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer. We conducted the hospital-based case-control study at the university hospital between 2003 and 2006. Cases were 130 high-grade CIN and 43 cervica...

Full description

Saved in:
Bibliographic Details
Published in:Archives of pharmacal research 2009, 32(7), , pp.1013-1018
Main Authors: Jeong, Nan-Hee, Woo, Mi-Kyung, Lee, Nak-Woo, Hur, Sook-Jin, Choi, Kum-Sook, Kim, Hong-Jin
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies, Viral - blood
Asian Continental Ancestry Group
Capsid Proteins - immunology
Case-Control Studies
Cervical Intraepithelial Neoplasia - ethnology
Cervical Intraepithelial Neoplasia - pathology
Cervical Intraepithelial Neoplasia - virology
Enzyme-Linked Immunosorbent Assay
Female
Human papillomavirus 16 - immunology
Human papillomavirus 18 - immunology
Humans
Korea - epidemiology
Medicine
Middle Aged
Pharmacology/Toxicology
Pharmacy
Prognosis
Seroepidemiologic Studies
Time Factors
Uterine Cervical Neoplasms - ethnology
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - virology
Virion - immunology
약학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to determine the prevalence of HPV-16/18 antibodies in Korean women with high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer. We conducted the hospital-based case-control study at the university hospital between 2003 and 2006. Cases were 130 high-grade CIN and 43 cervical cancer patients and the control group was 106 women showing normal cervical cytology. Enzyme-linked immunosorbent assays were performed for HPV-16/18 L1 virus-like particles (VLPs) as an antigen. Seropositivity for HPV-16 VLP and HPV-18 VLP was found in 67.4% and 30.2% of cancer patients and 59.2% and 20.0% of high-grade CIN patients, respectively. Seropositivity for HPV-16 with high-grade CIN (OR 6.91; 95% CI 3.74–12.76) and cervical cancer (OR 8.99; 95% CI 3.88–20.84) presented significant associations, as did seropositivity for HPV-18 (high-grade CIN: OR 3.64; 95% CI 1.67–7.95, cervical cancer: OR 6.82; 95% CI 2.52–18.45). Patients with both HPV-16 and 18 seropositivity were 9.38 times (95% CI 2.98–29.51) more likely to have high-grade CIN and 17.05 times (95% CI 4.55–63.87) more likely to have cancer. Both HPV 16 and 18 L1 VLP serology is the clear disease predictors of presence of high-grade CIN and cervical cancer.
ISSN:0253-6269
1976-3786
DOI:10.1007/s12272-009-1706-z